CN102526333A - Composition for regulating blood fat and protecting heart and blood vessels - Google Patents
Composition for regulating blood fat and protecting heart and blood vessels Download PDFInfo
- Publication number
- CN102526333A CN102526333A CN2011100006606A CN201110000660A CN102526333A CN 102526333 A CN102526333 A CN 102526333A CN 2011100006606 A CN2011100006606 A CN 2011100006606A CN 201110000660 A CN201110000660 A CN 201110000660A CN 102526333 A CN102526333 A CN 102526333A
- Authority
- CN
- China
- Prior art keywords
- compositions
- blood
- natto
- vitamin
- phytosterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition for regulating blood fat and protecting heat and vessels. The composition comprises rhodiola rosea compound powder, red yeast rice, phytosterol, natto and vitamin B complex, wherein a preset proportion of the rhodiola rosea compound powder to the red yeast rice and the phytosterol to natto and vitamin B complex in percentage by weight is (54-79): (14-39): (7-32). The composition can be used for reducing the myocardial oxygen consumption and oxygen consumption index, has a certain effect of reducing the blood pressure and the heart rate, ensures that the blood fat concentration of a user can be effectively reduced and the metabolic capacity of the user can be effectively improved, and has the function of protecting heart and blood vessels.
Description
Technical field
The invention relates to a kind of compositions, particularly relevant for a kind of adjustment blood fat and protect cardiovascular compositions.
Background technology
So-called cardiovascular disease comprises apoplexy, heart disease, hypertension and hyperlipidemia etc.In recent years, these diseases have become the No.1 killer of each advanced country.In the Taiwan, second and third and ten that are in compatriots' ten big causes of the death because of the dead death toll of cardiovascular disease, also thereby cause regretting of countless families.
Wearing out of hyperlipemia and vascular function is the significant risk factor of cardiac trigger angiopathy.The too many oils and fats of picked-up or the food of picked-up high heat in diet on ordinary days, after the metabolism, fatty consistency increases in the blood, makes fatty easy blocking in blood vessel, causes that vessel wall thickening, aperture diminish etc. in vivo.Heart must extra increase strength come pumping blood, just can make blood transport to perienchyma, and blood circulation is discharged for nutrition supply, the refuse of health and the purpose of gas exchange to satisfy.These tremulous pulse thickenings, the physiological change that anchyloses can make blood pressure increasing, systolic pressure increase, and make the vascular pressure of periphery increase, and cause the hypertrophy of left ventricle, and dysarteriotony increases, even also can cause the danger of arteriosclerosis.
On the treatment cardiovascular disease, all be to improve earlier through the mode of diet and motion, if can't improve the time, just treat through medicine.Except changing dietary habit (its comprise adopt low cholesterol, low salt, balanced diet low in calories, absorb the vegetable and fruit of high fiber etc.) more, keep SBW, keep good mood, keep normal work and rest, giving up the bad habits such as smoking excessive drinking, also can choose suitable nutriment.Therefore, to be fit to popular receptible nutriment be important problem in exploitation.
Summary of the invention
Because the problem that above-mentioned prior art exists, the object of the invention are exactly a kind of adjustment blood fat being provided and protecting cardiovascular compositions, to reach the effect of blood fat reducing.
According to the object of the invention, propose a kind of adjustment blood fat and protect cardiovascular compositions, it comprises Radix Rhodiolae compound recipe powder, Monas cuspurpureus Went, phytosterol, natto and vitamin B crowd.Wherein, Radix Rhodiolae compound recipe powder, Monas cuspurpureus Went, phytosterol, natto and vitamin B crowd mix with a predetermined ratio.
Wherein, Radix Rhodiolae compound recipe powder: Monas cuspurpureus Went and phytosterol: natto and vitamin B crowd's predetermined ratio is 54-79: 14-39: the 7-32 percentage by weight.
Wherein, Radix Rhodiolae compound recipe powder can comprise Lip river god, Radix Rhodiolae, Radix Salviae Miltiorrhizae, Folium Mori, Semen Cassiae, Folium Nelumbinis, celestial short, bristly hair or beard, Radix Glycyrrhizae or its combination.
Wherein, Monas cuspurpureus Went can comprise MonacolinK (monacolin K), and natto then comprises nattokinase (Nattokinase).
Wherein, Powdered, graininess or liquid that compositions of the present invention can be maybe can be the pattern of lozenge, capsule, tablet, powder, ointment or spray etc.
Wherein, compositions of the present invention can more comprise medicine and an acceptable excipient of food or an additive.The optional free flavoring agent of excipient or additive, sweetener, antiseptic, antioxidant, chelating agen, etc. in the group that forms of penetrating agent, lubricant, lozenge adjuvant, coloring agent, wetting agent, bonding agent and medical compatible supporting agent.
Wherein, compositions of the present invention can oral mode give.
Hold the above, comply with adjustment blood fat of the present invention and protect cardiovascular compositions, it can have one or more following advantage:
(1) because of compositions of the present invention contains Radix Rhodiolae compound recipe powder, it can reduce myocardial oxygen consumption and oxygen consumption index, has necessarily to bring high blood pressure down and the effect of the heart rate that slows down.
(2) Monas cuspurpureus Went in the compositions of the present invention contains the metabolite (active component) of itself: MonacolinK (monacolin K), it can suppress the HMG-CoA reduction enzyme (3-hydroxy-3-methyl-glutaryl-CoA reductase) in the cholesterol synthesis step.The structure of phytosterol is then similar with body's cholesterol, and it can absorb with the competition of animality cholesterol in intestinal.Therefore, continue practical compositions of the present invention, can make the effective blood fat reducing concentration of user.
(3) natto (containing nattokinase) in the compositions of the present invention not only can suppress the formation of thrombosis, has more thrombolytic effect.And the vitamin B crowd serves as the role of coenzyme in vivo, and it can engage with ferment and make its activation, and then makes that various metabolism are able to carry out in the health.Therefore, continue edible compositions of the present invention, can make the user effectively increase metabolic capacity and protection cardiovascular function.
Description of drawings
Fig. 1 respectively organizes the influence of diet to the hamster body weight for present embodiment.
Fig. 2 respectively organizes the influence of diet to triglyceride concentration in the hamster body for present embodiment.
Fig. 3 respectively organizes the influence of diet to HDL-C in the hamster body for present embodiment.
Fig. 4 respectively organizes the influence of diet to bran oxalic acid glutamic-pyruvic transaminase (GOT) in the blood plasma for present embodiment.
Fig. 5 respectively organizes the influence of diet to blood urea nitrogen in the hamster body for present embodiment.
Fig. 6 respectively organizes the influence of diet to kreatinin in the hamster body for present embodiment.
The specific embodiment
Embodiment 1: adjustment blood fat of the present invention and protect the composition of cardiovascular compositions
Adjustment blood fat of the present invention and protect cardiovascular compositions to comprise Radix Rhodiolae compound recipe powder, Monas cuspurpureus Went, phytosterol, natto and vitamin B crowd.Wherein, Radix Rhodiolae compound recipe powder, Monas cuspurpureus Went, phytosterol, natto and vitamin B crowd mix with a predetermined ratio, i.e. Radix Rhodiolae compound recipe powder: Monas cuspurpureus Went and phytosterol: natto and vitamin B crowd's predetermined ratio is 54-79: 14-39: the 7-32 percentage by weight.
Above-mentioned Radix Rhodiolae compound recipe powder can comprise Lip river god, Radix Rhodiolae, Radix Salviae Miltiorrhizae, Folium Mori, Semen Cassiae, Folium Nelumbinis, celestial short, bristly hair or beard, Radix Glycyrrhizae or its combination.And Monas cuspurpureus Went can comprise MonacolinK (monacolin K), and natto then can comprise nattokinase (Nattokinase).
In addition, compositions of the present invention more can comprise medicine and an acceptable excipient of food or an additive, and compositions of the present invention is made as Powdered, graininess, liquid or emulsion state etc.Again, compositions of the present invention can be passed through processed, and then its making is the pattern of lozenge, capsule, tablet, powder, ointment or spray etc., for the user edible (oral) at various ages.The user that for example age is less or the age is long, in the time of can't eating with the form of lozenge, the compositions of the present invention that can boiled water brews powder form is edible or edible with liquid form.
For capsule form, can be animality capsule or vegetalitas capsule, the animality capsule can be for example made by animal glue (gelatin), and the vegetalitas capsule can be for example made by sodium carboxymethyl cellulose (sodium carboxymethyl cellulose).For pure plain person, can eat by the vegetalitas capsule coats compositions of the present invention.Wherein, the optional free flavoring agent of excipient or additive, sweetener, antiseptic, antioxidant, chelating agen, etc. in the group that forms of penetrating agent, lubricant, lozenge adjuvant, coloring agent, wetting agent, bonding agent and medical compatible supporting agent.
Embodiment 2: preferred embodiment
Present embodiment verifies to have the adjustment blood fat and protect cardiovascular effect to confirm compositions of the present invention with zoopery and human experimentation.
(1) zoopery
(1) animal feeding
From platform large animal center, 56 of the male hamsters (male golden Syrian hamster) in age around buying, per four are put in the rearging cage.The environment of Animal House is controlled at 23.1 ℃, and relative humidity is at 40-60%.In addition, and with its illumination period of automatic timer control and dark period, wherein 6 of mornings be illumination period (light period) at 6 in evening, and be dark period (dark period) 6 of mornings at 6 in evening to next day, illumination period and dark period respectively 12 hours.The feeding manner of animal adopts the method (ad libitum) of freely ingesting; Earlier after the record daily intake; The throwing that gives capacity feedstuff and distilled water every day is given and will be made the unexpected scarcity of animal; And upgrade every day or the preceding pipe earlier of interpolation fresh feed is fed specimen, and its purpose is taken specimen for accomplish the empty stomach state as far as possible.
(2) feed formula
The feedstuff preparation procedure does, will be with semipurified diet (AIN-93G) (matched group) that contains soybean oil 7% or the adjustment feedstuff (high oils and fats hypercholesterolemia group) that contains 7% soybean oil, 8% seed oil and 0.2% cholesterol.To buy feedstuff and place-20 ℃ of reach in freezers to preserve, to guarantee the stability of composition.
(3) animal divides into groups
Earlier with (fat content 10%, cholesterol are 0.2ppm) two weeks of feeding hamster of general feeds 500I in the Animal House.After treating its adaptation, when six ages in week, be divided into seven groups at random, 8 every group according to body weight.Experimental period was carried out for eight weeks altogether, and measure body weight and write down it every day between feeding period.Divide into groups according to mainly being that (1) edible normal feedstuff (AIN-39G) is one group of matched group, feed with volume filtered water with pipe every day; (2) the high oils and fats high cholesterol diet of feeding; And add that every day, (it did not have the Radix Rhodiolae of interpolation compound recipe powder with pipe feeding Monas cuspurpureus Went, natto extract; Be called for short RN) be one group, and compositions of the present invention (being called for short RNH) comprise height, in and totally three groups of low three kinds of dosage, so relevant group has four groups; Reaching (3) blood sampling the last week (i.e. the 3rd week) or the first two week (i.e. the 6th week) taking blood lipid-lowering medicine ezetimibe (ezitimbe) is one group, adds up to totally six groups of groups, so whole experiment will be seven treated animals after adding matched group.The test dose that feeding RNH, RN and clinical hypolipidemic ezitimbe all set by its body weight change pipe feeding.Seven groups of experiments are divided into groups as follows:
(4) sample collection and analysis
All animals have influence on the value of endogenous blood fat to avoid the exophytic blood fat in the serum, and make blood to tend towards stability the last late fasting of blood sampling 14 hours.Whole experiment blood sampling time is respectively 0 week, the 4th week and had in the 8th week three times, and the blood sampling mode mainly obtains 1 milliliter blood with eye socket blood sampling mode, is placed in ice bath in the blood taking tube that contains EDTA.Afterwards, at centrifuge with 3,000rpm (under 1,570 * g), 4 ℃ the condition centrifugal 15 minutes, treat it and centrifugally get supernatant after intact that this supernatant is blood plasma, can carry out following analysis:
(A) blood fat matter testing index:
Comprise serum (or blood plasma; Below all with) triglyceride (and triglyceride, TG) and HDL-C (HDL-C).
(B) mensuration of liver function index GOT, GPT and renal function index blood urea nitrogen (BUN) and kreatinin (creatine) in the blood.Take out the blood supernatant, (FUJI DRI-CHEM FDC3000 V2.1-P03E) records blood fat and GOT, GPT, blood urea nitrogen and the kreatinin of animal with biochemical instruments.
The above statistics of the SPSS as a result software of testing is analyzed.All data are all with mean+SD (mean ± SD) expression.The blood sample project is carried out statistical analysis with the analysis of variance (two-way ANOVA test) of two-factor, and has statistical difference with p＜0.01 and 0.05 expression.
(5) compositions of the present invention is to the influence of hamster body weight
See also Fig. 1, it respectively organizes the influence of diet to the hamster body weight for present embodiment.Show that by result among the figure along with the increase of feeding week number, all laboratory animal body weight are all stable to rise.Wherein, the weight increase of the hamster of high lipid food group and RNH high dose group is maximum.And the hamster body weight of matched group is about intermediate degree, and the hamster body weight of itself and RNH low dose group and RN group is approaching.The body weight of dose groups is then more aforementioned again three groups low slightly among the RNH, and the minimum group of weight increase then is a positive matched group of taking hypolipidemic ezitimbe.Infer still tool toxicity to a certain degree of ezitimbe,, but still possibly cause this group body weight lighter though the dosage of ezitimbe that present embodiment uses belongs to safety.The above result can find the high lipid food feeding after eight weeks, causes the laboratory animal body weight to rise, and utilizes between ANOVA statistical analysis group and zero difference, and its result is as shown in table 1.
Table 1 is respectively organized hamster in 0,4,8 all body weight change
| Group | The 0th week | The 4th week | The 8th week |
| Matched group | 90.5±8.0 | 113.9±10.7 | 130.1±13.0 |
| The high lipid food group | 93.1±8.4 | 120.6±11.4 | 136.4±11.6 |
| The RNH high dose group | 96.8±8.9 | 122.6±12.7 | 134.6±16.3 |
| Dose groups among the RNH | 92.1±6.6 | 113.9±7.3 | 126.8±9.1 |
| The RNH low dose group | 93.3±8.0 | 115.9±8.6 | 130.5±10.0 |
| The RN group | 94.1±8.0 | 113.5±10.4 | 128.1±9.8 |
| Positive matched group | 96.8±8.6 | 115.1±13.2 | 125.3±15.9 |
(6) compositions of the present invention is to the influence of blood biochemical numerical value
Feeding has three blood sampling points in the zoopery in eight weeks altogether, is respectively 0 week before the feeding, 4 week of feeding back and after 8 weeks.The blood plasma of gained need be measured blood biochemical numerical value, comprises biochemical numerical value of blood fat and liver, kidney index, and each result is as shown in following.
(a) triglyceride
See also Fig. 2, it respectively organizes the influence of diet to triglyceride concentration in the hamster body for present embodiment.Among the figure, the triglyceride concentration in all laboratory animal blood, result measured around the is all apparently higher than the 8th week.Wherein, matched group except with RNH high dose group and RN group, itself and other group all has apparent difference (p＜0.05).And the 8th when week, the triglyceride concentration of RNH high dose group is showing and is being lower than high lipid food group (p＜0.01).In addition, dose groups among the high RNH, RNH low dose group, RN group and positive matched group, around the with the 8th all blood in triglyceride all slightly descend.And take hypolipidemic ezitimbe one or two weeks; All can reduce triglyceride amount in the blood; But only take two weeks of hypolipidemic ezitimbe, promptly measuring triglyceride concentration and high lipid food group the 8th week relatively, ability variant (p＜0.05) on statistics.The result can know thus, takes compositions of the present invention (being in particular high dose 333.4mg/kg/day) continuously after eight weeks, has the effect that reduces triglyceride concentration in the blood, and detail statistics difference is as shown in table 2.
Table 2 is respectively organized hamster and is changed at 0,4,8 all TG
*: represent p value＜0.05; * represents p value＜0.01
(b) HDL-C
See also Fig. 3, it respectively organizes the influence of diet to high density lipoprotein in the hamster body for present embodiment.Among the figure, the HDL-C of matched group is showing and is being lower than other groups (p＜0.01).Hence one can see that because of ingesting around the high lipid food or laboratory animal after eight weeks, through promoting HDL-C concentration, so that can transport cholesterol amount too much in the blood to reach the self-protection purpose.But this kind protective capability can't continue for a long time, finally still can cause cardiovascular disease.And positive matched group (taking ezitimbe) can reduce total cholesterol concentration in the blood, so the increase of the HDL-C concentration of this group of reasonable dismissal is less.
(c) liver function index
The liver function index of this enforcement detects bran oxalic acid glutamic-pyruvic transaminase (GOT) in the blood plasma, reaches bran propylhomoserin pyruvic glutamic-pyruvic transaminase (GPT).Usually weight increase or when taking the steroid therapy disease GOT and GPT value can rise.GOT and GPT are used to detect the hepatocyte injury degree, have suitable practicality.GPT is mainly from liver, and GOT is common in many extrahepatic tissues, like heart, skeletal muscle and kidney etc.Therefore clinically GPT to be only hepatocyte impaired than the specific index of tool.At the acute hepatitis initial stage, the serum GOT value is higher than GPT value (GOT/GPT＞1).Because GOT value descends comparatively fast, later stage GPT is than GOT high (GOT/GPT＜1), so during chronic hepatitis, GOT/GPT ratio is often less than 1.GOT and GPT concentration and the hepatic injury order of severity or the rare dependency of prognosis.
Owing to ingest eight weeks of high lipid food, its body weight of experiment hamster all increases, and respectively organizes the liver function whether diet can influence its hamster in order to detect, and therefore GOT in the hamster blood of each group of mensuration and GPT are as the foundation of liver function.
See also Fig. 4, it respectively organizes the influence of diet to GOT for present embodiment.By can knowing among the figure, and though be the normal feedstuff of feeding also or the GOT index of all laboratory animals of high lipid food do not have significant change, and experimental result is neither has a meaning on the statistical analysis difference.And, also do not have significant change (figure does not show) between each group to GPT.
(d) renal function index blood urea nitrogen and kreatinin
Blood urea nitrogen is proteinic metabolite.Protein is discharged in external via urine through renal secretion.If the concentration of blood urea nitrogen raises, just can react renal dysfunction.But, also can make the temporary rising of blood urea nitrogen concentration if lack moisture content, eat a large amount of protein foods, upper gastrointestinal hemorrhage, serious hepatopathy, infection, use steroid medicine, and factor affecting such as renal blood flow deficiency.From another angle, if because nephropathy is when causing blood urea nitrogen to rise, often nephropathy has proceeded to suitable degree, and the function of the early stage detecting of forfeiture that is to say that blood urea nitrogen can not reflect nephropathy in early days.Kreatinin is very stable renal function index, is usually used in assessing the order of severity of renal dysfunction, and the monitoring of the state of an illness of nephropathy, but is not suitable for the screening of early stage kidney disease.
Please consult Fig. 5 and 6 in the lump, what it was respectively present embodiment respectively organizes the influence of diet to blood urea nitrogen and kreatinin in the hamster body.In Fig. 5, the blood urea nitrogen of matched group is except having the statistical discrepancy with the high lipid food group, and matched group and other groups do not have statistical difference.In Fig. 6, dose groups, RNH low dose group and RN group among RNH high dose group, the RNH, its kreatinin does not obviously rise, so compositions of the present invention can't cause harmful effect to renal function.
(2) human experimentation
Present embodiment is called 17 experimenters altogether together, before test with after the test, respectively draws blood, to measure blood fat matter concentration.1 month by a definite date experimental period,, at duration of test, every experimenter continues orthobiosis, only in sooner or later getting involved compositions of the present invention after meal.In this embodiment, compositions of the present invention gives the experimenter with capsular mode, every day 2 times, and each 1 capsules, every capsule contains 500 milligrams the present composition altogether, and eats with eliminating cold for resuscitation water.
Before and after test; Experimenter's body weight, triglyceride, T-CHOL, HDL-C, low-density lipoprotein cholesterol (LDL-c) and bran amine acyltransferase (γ-glutamyl transferase; Be called for short GGT, be the exponential index of hepatitis) all can measure.The body weight aspect, test front and back and zero difference (average weight before the test is 59.358, is 59.44 after the test).The result of above-mentioned blood fat is as shown in table 3 below, and all data are all meansigma methods, and the formula of the range of decrease, increasing degree percentage ratio is (before the test back-test)/test preceding * 100.The result shows that triglyceride, T-CHOL, low-density lipoprotein cholesterol and bran amine acyltransferase all have a declining tendency, and high density lipoprotein then has the trend of rising.
The blood fat data of table 3 experimenter before and after test
In addition, sclerosis of blood vessels index (T-CHOL/HDL-C) aspect is 3.31 before the test, is 2.76 after the test, and it shows downward trend (range of decrease percentage ratio is-16.70).And coronary atherosclerosis index (low-density lipoprotein cholesterol/HDL-C) aspect is 2.02 before the test, is 1.64 after the test, its also have a declining tendency (range of decrease percentage ratio is-18.81).
Comprehensive The above results, after long-time edible compositions of the present invention, the eater can effectively reduce lipid in the blood (triglyceride, cholesterol and low-density lipoprotein cholesterol), and can't influence liver, renal function.In addition, the vitamin B crowd in the compositions of the present invention serves as the role of coenzyme in vivo, engages with ferment and makes its activation, and then make that various metabolism are able to carry out in the health.Therefore, continue edible compositions of the present invention, can make the user effectively increase metabolic capacity and protection cardiovascular function.
But the above-mentioned specific embodiment is exemplary, is to be the restriction that this patent is comprised scope in order better to make those skilled in the art can understand this patent, can not to be interpreted as; So long as according to spirit that this patent discloses done anyly be equal to change or modify, all fall into the scope that this patent comprises.
Claims (10)
1. adjust blood fat and protect cardiovascular compositions for one kind, it is characterized in that:
Comprise a Radix Rhodiolae compound recipe powder, a Monas cuspurpureus Went, a phytosterol, a natto and a vitamin B crowd;
Wherein, said Radix Rhodiolae compound recipe powder, Monas cuspurpureus Went, phytosterol, natto and vitamin B crowd mix with a predetermined ratio.
2. compositions as claimed in claim 1 is characterized in that: said Radix Rhodiolae compound recipe powder: said Monas cuspurpureus Went and phytosterol: said natto and vitamin B crowd's predetermined ratio is 54-79: 14-39: the 7-32 percentage by weight.
3. compositions as claimed in claim 1 is characterized in that: said Radix Rhodiolae compound recipe powder comprises Lip river god, Radix Rhodiolae, Radix Salviae Miltiorrhizae, Folium Mori, Semen Cassiae, Folium Nelumbinis, celestial short, bristly hair or beard, Radix Glycyrrhizae or its combination.
4. compositions as claimed in claim 1 is characterized in that: said Monas cuspurpureus Went comprises MonacolinK.
5. compositions as claimed in claim 1 is characterized in that: said natto comprises nattokinase.
6. compositions as claimed in claim 1 is characterized in that: said compositions is Powdered, graininess or liquid.
7. compositions as claimed in claim 1 is characterized in that: said compositions is the pattern of lozenge, capsule, tablet, powder, ointment or spray.
8. compositions as claimed in claim 1 is characterized in that: more comprise medicine and an acceptable excipient of food or an additive.
9. compositions as claimed in claim 8 is characterized in that: said excipient or additive be selected from by flavoring agent, sweetener, antiseptic, antioxidant, chelating agen, etc. in the group that forms of penetrating agent, lubricant, lozenge adjuvant, coloring agent, wetting agent, bonding agent and medical compatible supporting agent.
10. compositions as claimed in claim 1 is characterized in that: said compositions gives with oral mode.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110000660.6A CN102526333B (en) | 2011-01-04 | 2011-01-04 | Composition for regulating blood fat and protecting heart and blood vessels |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110000660.6A CN102526333B (en) | 2011-01-04 | 2011-01-04 | Composition for regulating blood fat and protecting heart and blood vessels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526333A true CN102526333A (en) | 2012-07-04 |
| CN102526333B CN102526333B (en) | 2014-04-09 |
Family
ID=46335153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110000660.6A Active CN102526333B (en) | 2011-01-04 | 2011-01-04 | Composition for regulating blood fat and protecting heart and blood vessels |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526333B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885306A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | Health-care food composite with function of assisting in reducing blood fat and preparation method thereof |
| CN104367624A (en) * | 2013-08-13 | 2015-02-25 | 刘炳喜 | Compound preparation containing red yeast rice |
| CN106036912A (en) * | 2016-06-02 | 2016-10-26 | 汤臣倍健股份有限公司 | Vitamin B composition adopting isotonic deep processing |
| CN114868927A (en) * | 2022-05-31 | 2022-08-09 | 黄河三角洲京博化工研究院有限公司 | Compound hypolipidemic capsule and preparation method thereof |
| CN114984196A (en) * | 2022-06-30 | 2022-09-02 | 北京悦意时光生物科技有限公司 | Natural plant composition for preventing and treating arteriosclerosis, preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999023996A2 (en) * | 1997-11-06 | 1999-05-20 | Peking University | Compositions containing red rice fermentation products, frementation processes and monascus strains therefor |
| CN101455359A (en) * | 2008-12-31 | 2009-06-17 | 西藏月王生物技术有限公司 | Oral preparation capable of promoting blood, reducing fat and protecting and strengthening health and preparation method thereof |
| CN101606695A (en) * | 2008-06-19 | 2009-12-23 | 刘泳宏 | A kind of natural liver-nourishing, toxin-expelling cholesterol-lowering porridge and preparation method |
| CN101664184A (en) * | 2009-09-22 | 2010-03-10 | 黑龙江省祖研北药科技开发有限责任公司 | Healthcare product for reducing blood fat and preparation method thereof |
| US20100273241A1 (en) * | 2009-04-24 | 2010-10-28 | Sunway Biotech Co., Ltd. | Method for manufacturing red mold dioscorea |
-
2011
- 2011-01-04 CN CN201110000660.6A patent/CN102526333B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999023996A2 (en) * | 1997-11-06 | 1999-05-20 | Peking University | Compositions containing red rice fermentation products, frementation processes and monascus strains therefor |
| CN101606695A (en) * | 2008-06-19 | 2009-12-23 | 刘泳宏 | A kind of natural liver-nourishing, toxin-expelling cholesterol-lowering porridge and preparation method |
| CN101455359A (en) * | 2008-12-31 | 2009-06-17 | 西藏月王生物技术有限公司 | Oral preparation capable of promoting blood, reducing fat and protecting and strengthening health and preparation method thereof |
| US20100273241A1 (en) * | 2009-04-24 | 2010-10-28 | Sunway Biotech Co., Ltd. | Method for manufacturing red mold dioscorea |
| CN101664184A (en) * | 2009-09-22 | 2010-03-10 | 黑龙江省祖研北药科技开发有限责任公司 | Healthcare product for reducing blood fat and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885306A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | Health-care food composite with function of assisting in reducing blood fat and preparation method thereof |
| CN104367624A (en) * | 2013-08-13 | 2015-02-25 | 刘炳喜 | Compound preparation containing red yeast rice |
| CN106036912A (en) * | 2016-06-02 | 2016-10-26 | 汤臣倍健股份有限公司 | Vitamin B composition adopting isotonic deep processing |
| CN114868927A (en) * | 2022-05-31 | 2022-08-09 | 黄河三角洲京博化工研究院有限公司 | Compound hypolipidemic capsule and preparation method thereof |
| CN114984196A (en) * | 2022-06-30 | 2022-09-02 | 北京悦意时光生物科技有限公司 | Natural plant composition for preventing and treating arteriosclerosis, preparation method and application |
| CN114984196B (en) * | 2022-06-30 | 2023-01-06 | 北京悦意时光生物科技有限公司 | Natural plant composition for preventing and treating arteriosclerosis, preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526333B (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102355898B (en) | Agent for promoting energy consumption | |
| CN102665704A (en) | Compositions including pyruvate for companion animals and methods of use thereof | |
| CN101347193A (en) | Compound rice capable of providing balanced nutrition and preparing art thereof | |
| CN102526333B (en) | Composition for regulating blood fat and protecting heart and blood vessels | |
| US8829057B2 (en) | AMPK activating agent | |
| JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
| CN104366126A (en) | Poultry feed | |
| CN105747235B (en) | A kind of dietary composition that can improve metabolic syndrome symptom | |
| CN102920743A (en) | Application of spirulina in preparation of anti-hyperuricemia and anti-uarthritis medicine or health-care food | |
| JP2011207776A (en) | Adiponectin production-promoting agent | |
| UA124965C2 (en) | Composition comprising a pentose and polyphenolic compound | |
| JP2017538693A5 (en) | ||
| CN108112992A (en) | A kind of functional medicine nutrition loss of weight formula and method | |
| CN108685971A (en) | A kind of Weight reducing compound and its preparation method and application | |
| Lukitasari et al. | 28 Green tea extract administration had a beneficial effect on ppar alpha and ppar gamma gene expression in metabolic syndrome rat model | |
| CN101208351A (en) | Compounds for the treatment of non-autoimmune type 2 diabetes mellitus and/or syndrome x | |
| CN110393293A (en) | A kind of coronary heart disease tailored version clinical nutrition formula and preparation method thereof | |
| CN103384477B (en) | For having the composition of the functional food recovering blood constitute and function | |
| TWI441643B (en) | Composition for adjusting blood lipid and cardiovascular protection | |
| CN106819223A (en) | A kind of health-care milk tea and preparation method thereof | |
| CN109717330A (en) | Carp feed and preparation method thereof | |
| CN103355665B (en) | A kind of composition for auxiliary hyperglycemic | |
| KR101697260B1 (en) | Composition Comprising Voglibose As a Prebiotic for Improving Intestinal Microflora or Preventing Obesity | |
| JP2020152690A (en) | Lipid absorption inhibitor | |
| Nugroho et al. | 29 DOSE-DEPENDENT EFFECTS OF GREEN TEA EXTRACT ON ADIPONECTIN LEVEL AND ADIPONECTIN RECEPTOR GENE EXPRESSION IN METABOLIC SYNDROME RAT MODELS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 71 Keji 5th Road, Annan District, Tainan City, Taiwan, China Patentee after: UNI-PRESIDENT BIOTECH Co.,Ltd. Address before: No. 31, Gongye 2nd Road, Annan District, Tainan City Patentee before: UNI-PRESIDENT BIOTECH Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder |